(World Health Organization, 2021, World Alzheimer’s Report, 2015)
Psychedelics are potent agonists of the serotonin receptor 5HT-2AR but can also activate other receptors of the brain, impacting numerous brain functions potentially involved in dementia.
Our molecules have specific beneficial characteristics including best onset time of action and administration modes to be taken at home. These molecules are being created to be perfectly suited to the dementia patent population.
Our drug discovery process begins with artificial intelligence algorithms that screen thousands of molecules to predict the top drug candidates for further investigation (also known as “in silico screening”). These advanced algorithms can evaluate entire molecule libraries within hours or days, significantly reducing drug discovery timelines and costs — while also increasing the likelihood of success by allowing a larger number of candidates to be screened.
Creating the 2nd Generation of Psychedelic Compounds.
Using 1st generation psychedelic compounds such as Psilocybin, LSD, and DMT as a scaffold, we are developing novel, next generation psychedelic compounds that are more suitable for the dementia population. In addition, we are retaining the benefits of the 1st generation compounds: behavioral modulation, neurogenesis, neuroplasticity, and anti-inflammation.
We are at the forefront of an abundant market opportunity, always looking for the right entities to invest in us and share our mission!
